Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
Propanc Biopharma, Inc. announced the publication of key research findings on recombinant trypsinogen and chymotrypsinogen production in a respected peer-reviewed journal. This work supports the development of a recombinant backup clinical compound (rec-PRP) to their lead product candidate PRP, targeting metastatic cancer from solid tumors. The rec…